Clinical trials
Alcohol-related Liver Disease clinical trials
Below are recruiting alcohol-related liver disease clinical trials, each written for real people, not researchers. We’re tracking 23 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06749990Recruiting
Alcohol relapse risk after liver transplant
This study looks at why some people with alcohol-related liver disease start drinking again after a liver transplant. It aims to find factors that increase or decrease that risk.
BolognaAges 18 years+ - NCT07450144Recruiting
Chatbot to Help Reduce Alcohol in Fatty Liver Disease
This study tests a chatbot that helps people with fatty liver disease reduce how much they drink. If you drink regularly and are ready to change, this tool could support you.
Hong KongAges 18 years+ - NCT06514300Enrolling by invitation
Study of muscle fat in fatty liver disease
This study looks at how fat in the muscles may affect liver disease in people with fatty liver and related conditions like obesity or diabetes. It aims to better understand the connection between muscle fat and liver health.
BrusselsAges 18–75 - NCT06613698RecruitingPhase 2
Testing an investigational drug for alcohol-related liver disease
This trial tests whether a new drug, GSK4532990, is safe and effective compared to a placebo in adults aged 18 to 70 with liver disease caused by alcohol use. The study aims to see if the drug can help treat advanced chronic liver disease.
Chandler, ArizonaAges 18–70 - NCT06305624Recruiting
Smartphone app to help people with alcohol-related liver disease stop drinking
This trial tests whether a smartphone program can help people with alcohol-related liver disease reduce or stop drinking. If you have liver disease related to alcohol and have used alcohol in the past 6 months, this app-based support may be for you.
Lansing, MichiganAges 18 years+ - NCT04400604Recruiting
Study of liver disease risk from heavy alcohol use
This study looks at people with heavy alcohol use who may have alcohol-related liver damage. It aims to better understand liver disease risk and how it changes over time, using blood tests, some scans, and possibly stored tissue.
LilleAges 18–75 - NCT05623150Recruiting
Biopsy-based study for alcohol and metabolic liver disease
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
NiceAges 18 years+ - NCT05855031Recruiting
Liver care support for people getting alcohol-use treatment
This trial looks at liver-focused care for people receiving outpatient treatment for alcohol dependence or alcohol-related harmful drinking. It may help by checking and improving how your liver health is supported while you stay in alcohol-use treatment.
KøgeAges 18–110 - NCT06269510Recruiting
Study to help alcohol-related liver disease patients drink less
This study is testing new ways to help people with alcohol-related liver disease reduce their drinking. Researchers will check if a program offered through your regular liver clinic can help you drink less and stay healthier.
Detroit, MichiganAges 18 years+ - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT06493773Recruiting
Alcohol help for new liver disease diagnosis
This trial tests a program to help people recently diagnosed with alcohol-related liver disease cut back on drinking. If you qualify, you may get support to improve your liver health.
Køge, KøgeAges 18 years+ - NCT06636227RecruitingPhase 1
Diclofenac dose study for alcohol use disorder
This study tests whether different doses of diclofenac, an anti-inflammatory drug, can help people reduce heavy drinking. It looks at how the drug affects drinking patterns and overall health.
Catonsville, MarylandAges 21–65 - NCT06994962Recruiting
Smartphone app to reduce heavy drinking in young adults
This study tests a smartphone app designed to help young adults (ages 18–25) drink less alcohol. If you're a heavy drinker and want to use technology to cut back, this app might be a good fit for you.
Boston, MassachusettsAges 18–25 - NCT07060547Recruiting
Blood test for alcohol-related liver disease
This study tests a new blood test (HepQuant DuO) to see how well it measures liver function in people with alcohol-related liver disease. If you have liver damage from alcohol and either a recent serious liver flare-up or also a fatty liver condition (NASH), this study may help your doctors understand your liver better.
Redwood City, CaliforniaAges 18 years+ - NCT07169526Recruiting
Health literacy and confidence in alcohol-related liver cirrhosis
This study looks at how well patients with alcohol-related liver cirrhosis understand health information and feel confident managing their health. It aims to find ways to support patients better.
HanoverAges 18–99 - NCT04234139Enrolling by invitation
Study of severe alcoholic hepatitis patients before early liver transplant
This study follows people with severe alcoholic hepatitis who are being considered for an early liver transplant before they’ve been sober for 6 months. It aims to better understand this group’s situation and ethics/safety as early transplantation plans are made.
Baltimore, MarylandAges 18 years+ - NCT04971577RecruitingPhase 2/Phase 3
Simvastatin for alcohol-related liver scarring in stable adults
This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.
BarcelonaAges 18 years+ - NCT04781322RecruitingPhase 1
Study drug to reduce LDL cholesterol effects in heavy drinkers
This Phase 1 study tests how safe a cholesterol-lowering antibody (alirocumab) is in people who drink heavily but are not seeking alcohol treatment. It also looks at early drug effects in the body to see how it might change cholesterol-related signals.
Bethesda, MarylandAges 21–65 - NCT07272200Recruiting
Genes and alcohol in liver cancer: a study
This study looks at how your genes and alcohol use together affect the risk of liver cancer. It may help find ways to prevent cancer in people with fatty liver disease or moderate alcohol intake.
Milan, MilanoAges 45–75 - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT07440511Recruiting
Spleen stiffness test for advanced liver scarring
This study tests a new way to measure liver scarring using a non-invasive ultrasound of the spleen (spleen stiffness measurement). It's for people with fatty liver disease (MASLD) who have advanced fibrosis (scarring) to see if this method can accurately detect the severity of liver damage.
RomeAges 18 years+ - NCT07381257RecruitingEarly Phase 1
Rifaximin for fatty liver disease
This trial tests if rifaximin, a gut medication, can help reduce liver fat in people with metabolic fatty liver disease. It may be an option if you have at least one metabolic risk factor and a certain amount of liver fat.
ShanghaiAges 18–75 - NCT07382349Recruiting
Decision support tools for fatty liver disease
This study tests electronic tools to help doctors identify and care for patients with steatotic liver disease (fatty liver). If you have risk factors like diabetes or elevated liver enzymes, this trial may help improve your care.
Nashville, TennesseeAges 18 years+
Hear when a new Alcohol-related Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alcohol-related liver disease?
- Yes. Clin2 currently lists 23 recruiting alcohol-related liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alcohol-related liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alcohol-related liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.